LGD 4033

LGD 4033 Dragon Pharma

Ligandrol, also known as LGD-4033, is a selective androgen receptor modulator (SARM) that has been studied for its potential therapeutic effects in various medical fields, particularly in the treatment of musculoskeletal conditions and conditions associated with muscle wasting.

References

Research published in the "Journal of Cachexia, Sarcopenia and Muscle" suggests that Ligandrol may help increase muscle mass and physical function in elderly individuals, thereby reducing the risks associated with age-related muscle loss (sarcopenia). It has also been evaluated for its efficacy in improving muscle strength and bone density in conditions such as osteoporosis.

However, it is important to note that while promising, these studies are typically conducted in small populations and under controlled conditions. The long-term safety profile of Ligandrol is not fully established and more extensive research is required to determine its full range of effects and potential side effects. It is essential that individuals consult with healthcare professionals and adhere to regulated medical protocols when considering the use of SARMs like Ligandrol.

Some of the key sources that provide a scientific understanding of SARMs, including Ligandrol, are "Selective androgen receptor modulators (SARMs): a novel class of androgen receptor ligands" by Gao and Dalton in the "Journal of Medicinal Chemistry" and "The Safety, Pharmacokinetics, and Effects on Body Composition and Physical Performance in Older Men and Postmenopausal Women of a Novel Nonsteroidal Selective Androgen Receptor Modulator (LGD-4033)" by Bhasin et al. in "The Journals of Gerontology Series A: Biological Sciences and Medical Sciences."

These studies underscore the need for further investigation into the therapeutic potential and safety of Ligandrol before it can be widely recommended for clinical use.